Cellular Intelligence | formerly Somite AI Information

Cellular Intelligence is building a universal foundation model for cell signaling to understand, predict, and ultimately control how cells behave, transforming biology from trial and error into an engineering discipline. A clinical-stage AI company, Cellular Intelligence holds the global rights to STEM-PD, an investigational Phase 2-ready cell therapy for Parkinson's disease with FDA Fast Track designation, acquired from Novo Nordisk. The company's founding team includes repeat AI entrepreneur Micha Breakstone, Ph.D. (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT, and five professors from Harvard Medical School, the University of Pennsylvania, and the University of Washington, collectively holding five National Academy memberships. Based in Boston, Cellular Intelligence has raised more than $70M from Khosla Ventures, the Chan Zuckerberg Initiative, Novo Nordisk, AMD Ventures, and others.